Ketamine Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Ketamine clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Natural History of Depression, Bipolar Disorder and Suicide Risk

Molecular Mechanisms of Pharmacological ActionDepressive SymptomsSuicide+18 more
National Institute of Mental Health (NIMH)500 enrolled1 locationNCT06462196
Recruiting
Early Phase 1

Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study

DepressionEsketamineAdolescent+1 more
Min Su220 enrolled2 locationsNCT07247968
Recruiting
Phase 2

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

DepressionDepressive DisorderMolecular Mechanisms of Pharmacological Action+10 more
National Institute of Mental Health (NIMH)50 enrolled1 locationNCT06511908
Recruiting
Phase 4

Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia

EsketamineDexmedetomidinePreoperative Anxiety+5 more
Second Affiliated Hospital of Wenzhou Medical University80 enrolled2 locationsNCT06853431
Recruiting
Not Applicable

Effect of Subanesthetic Dose of Esketamine on Sleep Quality

Breast Cancer SurgeryInsomniaEsketamine
Nanjing First Hospital, Nanjing Medical University184 enrolled1 locationNCT06773143
Recruiting
Phase 4

ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression

Treatment Resistant DepressionKetamine
University of Saskatchewan62 enrolled1 locationNCT03272698
Recruiting
Phase 3

Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting

MidazolamDepressive SymptomSevere Depression+16 more
Theresa Jacob, PhD, MPH40 enrolled1 locationNCT06752759
Recruiting
Not Applicable

Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease

EsketamineDeep Brain StimulationPD - Parkinson's Disease
Beijing Tiantan Hospital102 enrolled1 locationNCT06543563